TNFRSF17 and neoplasm: Although BCMA is a promising target, challenges such as its low level expression in some patients and antigen-negative tumor escape due to BCMA downregulation or shedding may compromise the clinical efficacy of BCMA-targeted CAR-T cell therapy.